Key Highlights

  • Shares rose in today's session to around $1,178, building on a recent rebound from earlier weakness.
  • New data showed more biomarker changes when Taltz and Zepbound were used together versus Taltz alone, as early as week 12.
  • By week 36, the combination was linked to changes in 482 proteins versus 140 for Taltz alone.
  • Roughly 61% of people with psoriasis in the U.S. also have obesity or a weight-related health condition.

New Data Points to a Deeper Psoriasis-Obesity Link

Eli Lilly (NYSE:LLY) shares rose in today's session after the company presented new exploratory data from its TOGETHER-PsO trial, which studies the combined use of Taltz, its psoriasis treatment, and Zepbound, its weight-loss drug, in patients who have both conditions. The data was presented at the Fall Clinical Dermatology Conference 2026 in Las Vegas.

The analysis found that patients using both drugs together showed broader changes in disease-related and metabolic biomarkers compared to those using Taltz alone, with differences appearing as early as week 12 of treatment.

Immune and Metabolic Pathways Move Together

By week 36, the combination therapy was associated with changes in 482 proteins and 467 genes, compared to 140 proteins and just 16 genes for Taltz alone. Researchers also observed larger reductions in inflammatory immune activity, including markers tied to neutrophils, a type of immune cell involved in inflammation.

These biomarker findings build on earlier TOGETHER-PsO results showing that the combination delivered better skin clearance and meaningful weight reduction than Taltz alone through week 36, with those benefits maintained or improved through week 52.

A Mega-Cap Pharma Name With a Deep Pipeline

Eli Lilly carries a market Capitalization above $1.1 trillion, with a diversified portfolio spanning diabetes, obesity, oncology, and immunology treatments. The company's shares have also drawn recent attention from research firms following a price target increase tied to raised 2026 Revenue guidance.

Outlook: Combination Therapy Data Could Reshape Treatment Approach

With roughly 61% of U.S. psoriasis patients also managing obesity or a related condition, the new data adds to a growing case for treating both conditions together rather than separately. Investors will likely watch for further trial results and any guidance update at the company's upcoming quarterly report.